1. Home
  2. ADVB vs ZDAI Comparison

ADVB vs ZDAI Comparison

Compare ADVB & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVB
  • ZDAI
  • Stock Information
  • Founded
  • ADVB 2014
  • ZDAI 2022
  • Country
  • ADVB United States
  • ZDAI Hong Kong
  • Employees
  • ADVB N/A
  • ZDAI N/A
  • Industry
  • ADVB Medical Specialities
  • ZDAI General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • ADVB Health Care
  • ZDAI Consumer Discretionary
  • Exchange
  • ADVB Nasdaq
  • ZDAI Nasdaq
  • Market Cap
  • ADVB 20.8M
  • ZDAI 20.6M
  • IPO Year
  • ADVB 2025
  • ZDAI 2024
  • Fundamental
  • Price
  • ADVB $0.69
  • ZDAI $0.88
  • Analyst Decision
  • ADVB
  • ZDAI
  • Analyst Count
  • ADVB 0
  • ZDAI 0
  • Target Price
  • ADVB N/A
  • ZDAI N/A
  • AVG Volume (30 Days)
  • ADVB 57.0K
  • ZDAI 301.1K
  • Earning Date
  • ADVB 08-03-2025
  • ZDAI 08-15-2025
  • Dividend Yield
  • ADVB N/A
  • ZDAI N/A
  • EPS Growth
  • ADVB N/A
  • ZDAI N/A
  • EPS
  • ADVB N/A
  • ZDAI N/A
  • Revenue
  • ADVB N/A
  • ZDAI $17,166,534.00
  • Revenue This Year
  • ADVB N/A
  • ZDAI N/A
  • Revenue Next Year
  • ADVB N/A
  • ZDAI N/A
  • P/E Ratio
  • ADVB N/A
  • ZDAI $28.07
  • Revenue Growth
  • ADVB N/A
  • ZDAI 56.11
  • 52 Week Low
  • ADVB $0.69
  • ZDAI $0.37
  • 52 Week High
  • ADVB $4.10
  • ZDAI $107.36
  • Technical
  • Relative Strength Index (RSI)
  • ADVB N/A
  • ZDAI N/A
  • Support Level
  • ADVB N/A
  • ZDAI N/A
  • Resistance Level
  • ADVB N/A
  • ZDAI N/A
  • Average True Range (ATR)
  • ADVB 0.00
  • ZDAI 0.00
  • MACD
  • ADVB 0.00
  • ZDAI 0.00
  • Stochastic Oscillator
  • ADVB 0.00
  • ZDAI 0.00

About ADVB Advanced Biomed Inc. Common Stock

Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

Share on Social Networks: